Investors’ outlook regarding the stock price performance over the year has been split, with some feeling optimistic and others feeling pessimistic, as it’s been a mixed bag. The index has shown a price gain of 490.14% this year. Over the last six months, there has been a weaker performance of 94.66%. The price of VRNA fallen by 7.92% during the last 30 days period. For the last 5-days stocks have slided -3.04%.
In terms of market performance, Verona Pharma Plc ADR had a somewhat regular. The highest value for the stock in the past year was $99.01 on 06/24/25, while the lowest value was $15.15 on 07/05/24.
52-week price history of VRNA Stock
The history of a stock’s 52-week high and low prices can provide important information about its current state and future potential. Verona Pharma Plc ADR’s current trading price is -7.55% away from its 52-week high, while its distance from the 52-week low is 504.23%. The stock’s price range for this period has been between $15.15 and $99.01. The Healthcare sector company’s shares saw a trading volume of about 0.44 million for the day, which was lower than the average daily volume of 1.4 million over the last three months.
The Connection Between Financial Performance and Market Capitalization
Verona Pharma Plc ADR (VRNA) has experienced a quarterly rise of 51.82% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 7.79B and boasts a workforce of 209 employees.
How Moving Averages and Trading Volume Data Work Together
VRNA’s Debt-to-Equity Ratio: A Comprehensive Review
A key metric for assessing a company’s financial well-being and market status is the debt-to-equity (D/E) ratio. This ratio is derived by dividing a company’s total liabilities by its shareholders’ equity, and it demonstrates the level of debt a company uses to support its assets relative to shareholder equity. At the time of writing, the total D/E ratio for VRNA stands at 1.08. Similarly, the long-term debt-to-equity ratio is also 1.07.
